Remote Blood Biomarkers of Longitudinal Cognitive Outcomes in a Population Study
Open accessThe DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Objective: The longitudinal association of the blood biomarkers total tau (t‐tau), neurofilament light (Nf‐L), and glial fibrillary acidic protein (GFAP) with common sporadic Alzheimer disease (AD) and cognitive decline is not established. Methods: Using a single molecule array technology, ultrasensitive immunoassays for serum concentrations of t‐tau, Nf‐L, and GFAP were measured in a population sample of 1,327 participants (60% African Americans and women) who had a clinical evaluation for AD, had completed in‐home cognitive assessments, and had undergone 1.5T structural magnetic resonance imaging. Results: Higher concentrations of serum biomarkers were associated with the development of clinical AD; especially, the time‐specific associations were notable: t‐tau 8 to 16 years, and Nf‐L and GFAP 4 to 8 years prior to clinical AD. Serum biomarkers were associated with faster cognitive decline over 16 years; baseline t‐tau > 0.40pg/ml had 30% faster decline, Nf‐L > 25.5pg/ml had 110% faster decline, and GFAP > 232pg/ml had 130% faster decline compared to those in the lowest quartile. Participants with baseline GFAP > 232pg/ml showed 160% faster decline in hippocampal volume compared to those with values < 160pg/ml. Additionally, higher baseline t‐tau was associated with faster increase in 3rd ventricular volume, and baseline Nf‐L and GFAP were associated with faster decline in cortical thickness. Interpretation: Serum t‐tau, Nf‐L, and GFAP predict the development of sporadic AD and cognitive decline, and changes in structural brain characteristics, suggesting their usefulness not only as screening and predictive biomarkers, but also in capturing the pathogenesis of Alzheimer dementia. ANN NEUROL 2020;88:1065–1076
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hosmer, D. W., Lemeshow, S., & Sturdivant, R. X. (2013) · Wiley Series in Probability and Statistics · doi:10.1002/9781118548387 · Cited by 13,861
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Clinical and biomarker changes in dominantly inherited Alzheimer's disease
Bateman, R. J., Xiong, C., Benzinger, T. L. S., Fagan, A. M., Goate, A., Fox, N. C., Marcus, D. S., Cairns, N. J., Xie, X., Blazey, T. M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1202753 · Cited by 3,814 · cited 15×
“Our results build on the findings of serum Nf-L as a biomarker for familial AD7 and on the results of numerous studies of the proximate associations of CSF and plasma biomarkers of clinical AD.12,13,31,32 Our contributions stem from this study’s focus on frequent sporadic clinically diagnosed AD; its population-based,…”
ResultInfluentialOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070 · cited 15×
“Our results build on the findings of serum Nf-L as a biomarker for familial AD7 and on the results of numerous studies of the proximate associations of CSF and plasma biomarkers of clinical AD.12,13,31,32 Our contributions stem from this study’s focus on frequent sporadic clinically diagnosed AD; its population-based,…”
InfluentialDominantly Inherited Alzheimer Network, Preische, O., Schultz, S. A., Apel, A., Kuhle, J., Kaeser, S. A., Barro, C., Gräber, S., Kuder-Buletta, E., LaFougere, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-018-0304-3 · Cited by 927 · cited 1×
“been associated with AD(13) and cognitive impairment.(14,15) However, less is known of how these biomarkers are related to longitudinal cognitive outcomes over a decade, including the time-dependent development of clinical AD, and longterm changes in cognitive functioning and brain morphology.”
BackgroundNeurofilament light chain: A prognostic biomarker in amyotrophic lateral sclerosis
Lu, C.-H., Macdonald-Wallis, C., Gray, E., Pearce, N., Petzold, A., Norgren, N., Giovannoni, G., Fratta, P., Sidle, K., Fish, M., et al. (2015) · Neurology · doi:10.1212/wnl.0000000000001642 · Cited by 563
Blood-based NfL: A biomarker for differential diagnosis of parkinsonian disorder
Hansson, O., Janelidze, S., Hall, S., Magdalinou, N., Lees, A. J., Andreasson, U., Norgren, N., Linder, J., Forsgren, L., Constantinescu, R., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000003680 · Cited by 506
Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration
Weston, P. S. J., Poole, T., Ryan, N. S., Nair, A., Liang, Y., Macpherson, K., Druyeh, R., Malone, I. B., Ahsan, R. L., Pemberton, H., et al. (2017) · Neurology · doi:10.1212/wnl.0000000000004667 · Cited by 245 · cited 1×
“Plasma t-tau has been shown to be associated with a steeper decline in global cognition over 3 years(5) and Nf-L with short-term changes in cognition.(38) Our finding that serum t-tau level is a robust remote predictor of clinically diagnosed AD is compatible with recent findings that tauopathy seen on multitracer pos…”
Result
Cited by
Blood-based biomarkers for Alzheimer's disease: towards clinical implementation
Teunissen, C. E., Verberk, I. M. W., Thijssen, E. H., Vermunt, L., Hansson, O., Zetterberg, H., van der Flier, W. M., Mielke, M. M., & del Campo, M. (2022) · The Lancet Neurology · doi:10.1016/s1474-4422(21)00361-6 · Cited by 1,045
Blood GFAP as an emerging biomarker in brain and spinal cord disorders
Abdelhak, A., Foschi, M., Abu-Rumeileh, S., Yue, J. K., D’Anna, L., Huss, A., Oeckl, P., Ludolph, A. C., Kuhle, J., Petzold, A., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00616-3 · Cited by 807
Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer's disease
Pereira, J. B., Janelidze, S., Smith, R., Mattsson-Carlgren, N., Palmqvist, S., Teunissen, C. E., Zetterberg, H., Stomrud, E., Ashton, N. J., Blennow, K., et al. (2021) · Brain · doi:10.1093/brain/awab223 · Cited by 598
Blood phospho-tau in Alzheimer disease: analysis, interpretation, and clinical utility
Karikari, T. K., Ashton, N. J., Brinkmalm, G., Brum, W. S., Benedet, A. L., Montoliu-Gaya, L., Lantero-Rodriguez, J., Pascoal, T. A., Suárez-Calvet, M., Rosa-Neto, P., et al. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-022-00665-2 · Cited by 329
GFAP as a Potential Biomarker for Alzheimer’s Disease: A Systematic Review and Meta-Analysis
Kim, K. Y., Shin, K. Y., & Chang, K.-A. (2023) · Cells · doi:10.3390/cells12091309 · Cited by 309
“Plasma GFAP concentrations have been shown to correlate strongly with decreased cognitive function [5,33,80].”
BackgroundCicognola, C., Janelidze, S., Hertze, J., Zetterberg, H., Blennow, K., Mattsson-Carlgren, N., & Hansson, O. (2021) · Alzheimer's Research & Therapy · doi:10.1186/s13195-021-00804-9 · Cited by 300
Plasma proteomic profiles predict future dementia in healthy adults
Guo, Y., You, J., Zhang, Y., Liu, W.-S., Huang, Y.-Y., Zhang, Y.-R., Zhang, W., Dong, Q., Feng, J.-F., Cheng, W., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00565-0 · Cited by 293
Specific associations between plasma biomarkers and postmortem amyloid plaque and tau tangle loads
Salvadó, G., Ossenkoppele, R., Ashton, N. J., Beach, T. G., Serrano, G. E., Reiman, E. M., Zetterberg, H., Mattsson‐Carlgren, N., Janelidze, S., Blennow, K., et al. (2023) · EMBO Molecular Medicine · doi:10.15252/emmm.202217123 · Cited by 205
“…higher levels of plasma GFAP and increased risk of clinical progression and steeper rates of cognitive decline (even after adjusting for amyloid) (Rajan et al , 2020; Verberk et al , 2021; Ebenau et al , 2022), which supports a link with tau pathology given the known strong association between…”
BackgroundAlzheimer disease in African American individuals: increased incidence or not enough data?
Barnes, L. L. (2022) · Nature Reviews Neurology · doi:10.1038/s41582-021-00589-3 · Cited by 142
Self-citationAshton, N. J., Leuzy, A., Karikari, T. K., Mattsson-Carlgren, N., Dodich, A., Boccardi, M., Corre, J., Drzezga, A., Nordberg, A., Ossenkoppele, R., et al. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05253-y · Cited by 142
Brain injury in COVID-19 is associated with dysregulated innate and adaptive immune responses
Needham, E. J., Ren, A. L., Digby, R. J., Norton, E. J., Ebrahimi, S., Outtrim, J. G., Chatfield, D. A., Manktelow, A. E., Leibowitz, M. M., Newcombe, V. F. J., et al. (2022) · Brain · doi:10.1093/brain/awac321 · Cited by 90
“33,34 Larger cohorts will be required to replicate our COVID-19 finding and accurately delineate the association between late elevated total tau and clinical outcome, however the lack of association between initial disease severity and subsequent total tau elevation is tantalizing given the…”
Zhu, N., Santos-Santos, M., Illán-Gala, I., Montal, V., Estellés, T., Barroeta, I., Altuna, M., Arranz, J., Muñoz, L., Belbin, O., et al. (2021) · Translational Neurodegeneration · doi:10.1186/s40035-021-00275-w · Cited by 86
“Previous studies reported that the serum GFAP has potentials to predict future conversion to dementia in cognitively normal individuals, not only to AD, but also to other dementias including FTD [16, 17, 22].”
BackgroundResultBeyer, L., Stocker, H., Rujescu, D., Holleczek, B., Stockmann, J., Nabers, A., Brenner, H., & Gerwert, K. (2023) · Alzheimer's & Dementia · doi:10.1002/alz.12745 · Cited by 81
Metadata
- Authors
- Rajan, K. B., Aggarwal, N. T., McAninch, E. A., Weuve, J., Barnes, L. L., Wilson, R. S., DeCarli, C., & Evans, D. A.
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2020-09-29
- Volume
- 88
- Issue
- 6
- Pages
- 1065-1076
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- OpenAlex
- W3049747840
- Cited by
- 147
- References
- 13
- FWCI
- 13.72
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.